1. Home
  2. UBXG vs BOLD Comparison

UBXG vs BOLD Comparison

Compare UBXG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U-BX Technology Ltd. Ordinary Shares

UBXG

U-BX Technology Ltd. Ordinary Shares

HOLD

Current Price

$0.40

Market Cap

34.8M

Sector

N/A

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.54

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
UBXG
BOLD
Founded
2018
2018
Country
China
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
34.8M
36.5M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
UBXG
BOLD
Price
$0.40
$1.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
885.2K
374.5K
Earning Date
06-18-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.96
52 Week High
$4.49
$1.72

Technical Indicators

Market Signals
Indicator
UBXG
BOLD
Relative Strength Index (RSI) 31.33 63.36
Support Level N/A $1.12
Resistance Level $2.12 N/A
Average True Range (ATR) 0.29 0.07
MACD -0.03 -0.01
Stochastic Oscillator 0.11 50.00

Price Performance

Historical Comparison
UBXG
BOLD

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd focuses on providing value-added services using artificial intelligence-driven technology to businesses in the insurance industry, including insurance carriers and brokers. Its main offerings include three services/products: digital promotion services, risk assessment services, and value-added bundled benefits. The PRC operating entities help their institutional clients gain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or clients' promotion time on these channels. U-BX Beijing developed a unique algorithm named the Magic Mirror. The majority of revenue comes from digital promotion services. Geographically, all of the company's revenue is derived from Mainland China.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: